Sélectionner une page
Natural Law – Your Right to Try

Natural Law – Your Right to Try

Natural Law – Your Right to Try

Natural Laws are a body of unchanging moral principles derived from nature. As the basis for all human conduct, they transcend time, culture, and government. Aristotle is known as the father of Natural Law. In Rhetoric, he proposed that there is a “common law” or “higher law” that is according to nature.

The natural law framework led to the concept of “Natural Rights.” The philosopher John Locke defined Natural Rights as a person’s rights to life, liberty, and property. Locke believed that the most basic human law of nature is the preservation of humanity. To serve that purpose, he reasoned, individuals have both a right and a duty to preserve their own lives.

These principles have become universal with The Declaration of Independence (1776) of the United States, the Declaration of the Rights of Man and of the Citizen (1789) of France, the Universal Declaration of Human Rights (1948) of the United Nations as well as the European Convention on Human Rights (1953) of the Council of Europe.

The Federal Right to Try Act of 2017 is the most current way of expressing our natural right to restore our health and preserve our own lives. It gives new options to patients with life-threatening and debilitating conditions, who have failed – or are not amenable to – accepted surgeries, drugs, or devices.

Federal Right to Try Act - Ambrose Cell Therapy

There are a surprising number of adults living with complex chronic degenerative conditions, particularly those with multiple diseases (morbidities).

One such patient was Tony. In September 2018, he was facing multiple joint replacements and surgeries due to debilitating chronic inflammation and osteoarthritis in his knees, left hip, both shoulders, and fingers. Instead of operations or drugs, he exercised his ‘Right to Try” AMBROSE Cell Therapy. Now over a year and a half out, Tony is pleased to report his remarkable improvement in pain scores, mobility, function, and quality of life. Here is his inspiring Patient Reported Outcome.

Biodistribution of Adult Stem Cells

Biodistribution des cellules souches adultes

Biodistribution des cellules souches adultes

Mesenchymal Stem Cells

In 1991, Professor Arnold Caplan published the seminal paper, Mesenchymal Stem Cells (MSCs). In the article, he described MSCs as having the ability to differentiate and self-renew into multiple tissue types, as well as neurons and blood vessels. [1] In other words, they are ‘multipotent,’ meaning they can produce more than one type of specialized cell of the body, but not all types. Differentiation and self-renewal are the unique characteristics required of a cell to be a stem cell.

What Are Adult Stem Cells? | AMBROSE Cell Therapy

In the article’s introduction, he called MSCs, “the basis for the emergence of a new therapeutic technology of self-cell repair” (emphasis added). His tireless research gained extensive support from hundreds of other scientists. In fact, according to a PubMed search, there are now over 160,000 published papers that discuss MSCs. This vast body of literature has led to a broad agreement as to how these repair cells migrate to and repair diseased tissues and organs. The science has also progressed to include an understanding as to how MSCs restore normal function in our vascular, immune, and endocrine (hormone) systems.

Research has further progressed to include an appreciation of how MSCs do their job (and has led to a proposed new name for them). More on the new name later; first, here is the back story.

Biodistribution

Since the early days of research into MSCs, scientists have been on a quest to determine the optimum delivery route. Much like planning the most efficient course through a labyrinth-like city (such as London), they want our stem cells to stay clear of blind alleys, wrong-way streets, and circuitous routes. The investigators also recognize some courses may be riskier than others – even if seemingly more efficient per the map, e.g., directly injecting stem cells into the brain or the eye.

But there is a new angle to the planning process that is increasingly appreciated by researchers: The underlying role that low-level systemic inflammation (inflammaging) plays in chronic disease and the potential for stem cells to calm that down. More on inflammaging later; first, how do MSCs do their job?

Mechanisms of Action

Mechanism of action (MOA) refers to the way our stem cells (or drugs) produce their effect. In the case of MSCs, their MOAs are analogous to the fire department: They respond to a fire alarm – i.e., an inflammatory signal – and beeline to the source of it. MSCs have been called “guardians of inflammation.” [2] Once they get to the scene of the fire, they release hundreds of bioactive signaling molecules called “cytokines.” The cytokines activate the local cells in the neighborhood to do their jobs. This cell-to-cell communication is called the paracrine effect.

In short, since Dr. Caplan’s groundbreaking paper was published, researchers have verified that homing and the paracrine effect are the central roles of MSCs in the repair process. And so, that is why Prof. Caplan proposed changing the name to “Medicinal Signaling Cells.” [3]

Biodistribution Studies

Biodistribution studies have established that adult stem cells delivered IV migrate through the lungs and “park” there (“first-pass effect”) – and then move on. (There is some confusion as to whether the first-pass effect is a “dead-end street,” but suffice to say, research has established that it is not the case.) [4] [5] [6]

As they continue on their mission to fight inflammation and repair the body, they journey through the vascular system and organs to the spleen, our largest immune organ. They then route through the lymphatic system.

The lymphatic system, which runs parallel to the vascular system, is an essential part of the immune system. It carries lymph (a clear fluid containing a high number of a type of white blood cells called lymphocytes. Lymphocytes fight infection and destroy damaged or abnormal cells. They are abundant in the mixed population of cells accessed from our adipose tissue for cellular therapies.

Biodistribution Studies

A well-designed study of IV infusion of adult stem cells in baboons tracked the migration. The graph below shows distribution to all of the major internal body organs. [7]

Add to that, in a cardiac cell therapy study, researchers at Texas Heart Institute and MD Anderson tracked stem cells injected in the hearts of pigs. They also found the MSCs traveled through the blood vessel system into the spleen and then continued to move through the lymphatics. [8]

As a side note, lest we discount the potential of self-cell repair, a study in mice found that systemically delivered adult stem cells could repair chemically-induced corneal damage – without there being any of the MSCs directly applied to the cornea. [9]

Summary
For more on why AMBROSE accesses the MSCs and other regenerative cells from your adipose tissue, please read Why Adipose Tissue. Connecting this back to our Domaines d'intervention et Notre protocole, ADRCs, delivered IV, have the potential to home to all of the major organs and initiate a process of repair.


 

Chronic Inflammation – Is that all there is to disease?

Inflammation chronique - La maladie se résume-t-elle à cela ?

Inflammation chronique - La maladie se résume-t-elle à cela ?

L'inflammation systémique chronique (ICS) est un sujet d'actualité. Et pour cause, il est presque universellement reconnu que l'ICS est un coupable dans toutes les maladies chroniques du vieillissement.

De grands médias comme le Washington Post et New York Times ont consacré des articles à la police scientifique. Crue et brûlanteLe rapport de la Commission européenne sur la santé et la sécurité au travail, qui résume certaines des études éclairantes de la Harvard Medical School (et de ses institutions affiliées) sur le sujet, est disponible sur le site de la Commission européenne.

En accédant aux cellules souches (et à d'autres cellules régénératrices) présentes dans notre graisse (tissu adipeux), sous les auspices de la loi fédérale Right to Try Act de 2017, les personnes atteintes de maladies inflammatoires systémiques chroniques débilitantes ont accès à une nouvelle option pour améliorer leur qualité de vie. Vous pouvez en savoir plus sur la loi sur le droit à l'essai. ici.

Mais l'inflammation est-elle tout ce qu'il y a à faire ?
L'accent mis sur l'inflammation chronique (également connue sous le nom d'"inflammaging") a, dans de nombreux cas, servi à minimiser (ou même à ignorer) les autres facteurs qui sont également couramment impliqués dans les maladies chroniques. Nous reviendrons sur ce point dans un instant ; tout d'abord, l'histoire de l'inflammation et celle, largement méconnue, du plus grand besoin non satisfait dans le domaine des soins de santé - les patients atteints de maladies chroniques multiples.

Inflammation
L'inflammation n'est pas une idée nouvelle. Son histoire est longue et colorée. Des papyrus égyptiens datant de près de 5 000 ans mentionnent la chaleur et la rougeur comme étant naturellement associées à la maladie. D'un autre point de vue, au Ve siècle avant J.-C., Hippocrate décrivait l'aspect bénéfique de l'inflammation comme un élément précoce du processus de guérison après une lésion tissulaire.

En termes courants, les augmentations à court terme de l'inflammation (aiguë) sont essentielles à la réparation, voire à la survie, en cas de blessure physique ou d'infection, respectivement.

Cependant, il a été révélé que certains facteurs sociaux, environnementaux, liés à des traumatismes et au mode de vie peuvent rendre l'inflammation incontrôlable et la rendre chronique. L'inflammation chronique est comme un feu couvant à l'intérieur de l'organisme ; elle se propage lentement, allumant souvent plusieurs maladies chroniques (morbidités). Les patients souffrant de morbidités multiples représentent le problème le plus épineux dans le domaine des soins de santé.

Étant donné que les effets néfastes de l'inflammation sont largement reconnus, il existe un mouvement irrépressible dans le secteur des soins de santé (y compris chez les patients) pour faire quelque chose à ce sujet. Les médecins conventionnels prescrivent des médicaments pour supprimer l'inflammation, tandis que les médecins intégratifs recommandent des régimes et des compléments alimentaires pour la réduire. De plus en plus de personnes (des "inquiets" aux malades chroniques) boivent des jus verts et mangent des salades de chou frisé pour remplacer les boissons sucrées, le pain et les desserts qu'ils "appréciaient" auparavant au détriment de leur santé.

Pour ne pas être en reste, les scientifiques étudient les voies et les gènes de l'organisme qui transforment l'excès d'inflammation. sur avec l'espoir de découvrir de petites molécules pouvant être mises dans une pilule pour l'éteindre comme un interrupteur.

Mais malgré tout cela - et même si certaines personnes font état de bénéfices - l'assaut des maladies chroniques liées au vieillissement n'a pas été inversé et les prescriptions de médicaments, de chirurgies et d'appareils pour les combattre n'ont pas été ralenties.

Le bon côté des choses
En revanche, depuis plus de 20 ans, des centaines de chercheurs ont décrit dans plus de 10 000 articles évalués par des pairs qu'une population mixte de cellules souches et régénératives présentes dans notre graisse (tissu adipeux) peut non seulement améliorer les marqueurs inflammatoires, mais aussi traiter les multiples facteurs qui contribuent à la mauvaise santé résultant de l'inflammation.

En 2016, des chercheurs ont résumé la science et les études soutenant les attributs uniques des ADRC dans un article de synthèse intitulé Autologous Adipose Derived Regenerative Cells : A Platform for Therapeutic Applications.

Les résultats remarquables obtenus par Trish dans le cadre de son traitement de l'"hypermobilité", une maladie héréditaire du tissu conjonctif, illustrent parfaitement les avantages potentiels de la thérapie cellulaire AMBROSE. Sa maladie avait entraîné une inflammation chronique, des douleurs débilitantes et un handicap. Contrairement à d'autres membres de sa famille atteints de la même maladie, Trish est désormais en mesure de vivre pleinement sa vie. Ici est son histoire.

Compassion Not Greed, Right to Try – Basic Human Rights: Reversals of Disease & Disabilities

La compassion et non l'avidité, le droit d'essayer - les droits de l'homme fondamentaux : Inversion de la maladie et du handicap

Matthew Feshbach, fondateur et PDG d'Ambrose Cell Therapy, revient dans l'émission pour expliquer comment sa société fait des progrès étonnants pour aider ceux qui ont été laissés pour compte par la médecine traditionnelle. Il explique comment la graisse humaine stocke de puissantes cellules souches humaines qui peuvent être utilisées pour reconstruire les tissus, les muscles, réduire l'inflammation et bien plus encore. Il nous fait part de ses réussites et des possibilités étonnantes qui s'offrent à nous pour l'avenir.

Pour écouter le podcast, veuillez cliquer sur les liens ci-dessous :

Première partie & Partie 2

Real Stem Cell Therapy Outcomes

Résultats réels de la thérapie par cellules souches

Résultats réels de la thérapie par cellules souches

Matthew Feshbach CEO AMBROSE Cell Therapy - Real Stem Cell Therapy Outcomes

Click to listen in full to Episode 45 of Living Beyond 120 as AMBROSE CEO Matthew Feshbach delves into real patient stories and the importance of monitoring stem cell therapy outcomes.

CEO and Founder Matthew Feshbach recently returned as a guest on anti-aging and wellness podcast Living Beyond 120 to talk stem cell therapy outcomes and real AMBROSE patient stories.

Why Patient Outcomes Matter

With more than 98 million adults in the United States living with 2 or more chronic conditions, AMBROSE evaluates the common factors of chronic disease and addresses them in a single procedure utilizing patients’ own adult stem and regenerative cells derived from adipose (fat tissue).

AMBROSE operates under Texas “right to try” legislation (House Bill 810, also known as Charlie’s Law) and approaches investigational stem cell treatments at a serious clinical level, offering patients a safe, regulated environment in which to explore stem cells for improved symptoms, function and quality of life. AMBROSE patient outcomes are examined as part of the Adipose Cell Therapy for Chronic Inflammation (ACT-CI) registry study, conducted under said legislation, the purpose of which is to assess the safety, feasibility and effectiveness of using patient’s own cells to treat severe, chronic conditions.

By closely monitoring and reporting on our outcomes, we hope to help more patients gain access to this potentially life-changing therapy and to set a new standard of safety and care in the process.

“Real Stem Cell Therapy Outcomes” – The Interview

In this episode of Living Beyond 120, Dr. Jeffrey R. Gladden, MD, FACC, and host Mark Young talk with Feshbach about real patient stories, delving into stem cell therapy outcomes experienced by patients suffering from serious and debilitating conditions such as:

  • Multi-joint arthritis and facing joint replacement
  • Kidney failure
  • Lung disorders such as COPD and emphysema
  • Neurodegenerative conditions including Alzheimer’s, Parkinson’s and traumatic brain injury

In the hour-long podcast, they also discuss the role and appropriate use of stem cell therapy as well as ways to improve outcomes if they do take advantage of this kind of treatment. Listen to the full podcast here.

About Living Beyond 120

On this podcast focused on health and human longevity, Dr. Jeffrey R. Gladden, MD, FACC, and host Mark Young examine the latest scientific research, technology and bio-hacks to uncover the truth about the human body’s potential for extending both life and health span well past the what most people accept as biological fact. AMBROSE was featured in an earlier episode titled, “Stem Cell Therapy Now.”

AMBROSE CEO Matt Feshbach Featured on “Living Beyond 120” Podcast

AMBROSE CEO Matt Feshbach Featured on “Living Beyond 120” Podcast

AMBROSE CEO Matt Feshbach Featured on “Living Beyond 120” Podcast

Click to listen to the full podcast (Episode 26), “Stem Cell Therapy Now – An Interview with Matthew Feshbach”

Earlier this year, AMBROSE CEO and founder Matthew Feshbach was a featured guest on anti-aging and wellness podcast Living Beyond 120 with Dr. Jeffrey Gladden and Mark Young.

Stem Cell Therapy Now – The Interview

Matthew joined the conversation to share information about stem cell research and treatment, to discuss the differences between stem cell types and which are most effective for therapies focused on repair.

About Living Beyond 120

On this podcast focused on health and human longevity, Dr. Jeffrey R. Gladden, MD, FACC, and host Mark Young examine the latest scientific research, technology and bio-hacks to uncover the truth about the human body’s potential for extending both life and health span well past the what most people accept as biological fact.

The Cell Source Debate

Le débat sur les sources cellulaires

Le débat sur les sources cellulaires

Many sources of stem cells exist, not all of them are created equal. At AMBROSE, having examined these various sources and their functions, our interest is in the adult stem cells found in adipose tissue (fat).

Adipose-derived stem and regenerative cells (ADRCs) are scientifically validated to be more accessible, abundant and potent than the stem cell populations from bone marrow and umbilical cord blood. They also have an advantaged mix of cell types to rescue, repair and regenerate damaged tissues, organs and the systems—including the vascular, immune, autonomic, and endocrine (hormones)—of our bodies. In addition, the factors of age-related declines in yield and potency that are found in the in the bone marrow are not observed in ADRCS. [1] [2] [3]

What is a Stem Cell?

The term stem cell first appeared in the scientific literature some 150 years ago in the works of the eminent German biologist Ernst Haeckel (Haeckel, 1868). Haeckel, a major supporter of Darwin’s theory of evolution, drew a number of branching trees to represent the evolution of organisms by descent from common ancestors and called these trees ‘‘Stammba ̈ ume’’ (German for family trees or ‘‘stem trees’’). In this context, Haeckel used the term ‘‘Stammzelle’’ (German for stem cell) to describe these cells as the most basic cells in our body and from which all other cells are developed.

Embryonic Stem Cells

Embryonic stem cells (ESCs)—of which there are between 50 and 150—are developmental cells, meaning they develop into all of the cell lines of our body and those cells replicate. They are referred to as “totipotent stem cells,” being the only cells capable of giving rise to all cell types necessary to develop an embryo into a fully formed body.

ESCs can develop into each of the more than 200 cell types of the adult body when given sufficient and necessary stimulation for a specific cell type, however ethical and medical concerns surround their use. Due to this they have been the subject of only a small number of human trials and are illegal to use in nearly all developed countries including the US.

Adult Stem Cells

  • Hematopoietic Stem Cells – Blood cell forming stem cells found in the bone marrow and umbilical cord tissue and blood
  • Mesenchymal stem cells (MSCs) – Reparative stem cells found in every tissue of the body, most abundantly in our fat.

The term “adult stem cell” is cause for some confusion, as these are the cells we are born with. Adults and infants alike possess the same “adult” stem cells. Thus, a more accurate and descriptive name for these cells might be “repair cells,” for this is their function in a fully developed body. Adult stem cells do not grow a new heart, brain, or bones—they are purposed to keep what we have in good repair.

The history of adult stem cell research began in the 1950s, when researchers discovered that the bone marrow contains at least two kinds of stem cells. The first population, called hematopoietic stem cells (HSCs), forms all the types of blood cells in the body. HSCs make up approximately 99.9% of the stem cells in bone marrow and, as they are blood forming stem cells, they are used to treat blood cancers. Umbilical cord blood stem cells are also virtually all HSCs and have been approved for use to treat blood cancers as well.[4] There are stem cells in the umbilical cord tissue but as they are small in number per gram it is necessary to grow them out in a dish (culture).

The second population found in bone marrow is the mesenchymal stem cell (MSC).

The origin of the concept of a “mesenchymal” stem cell goes back to the pioneering experiments of Tavassoli and Crosby in the 1960s.[5] In 1991, Prof. Arnold Caplan from Case-Western University named the MSC. [6] According to a Medline search, there are now over 49,000 published papers on MSCs and they have been used in over 700 clinical trials. In 2016, Dr. Caplan, in MSCs—The Sentinel and Safe-Guards of Injury[7]  proposed renaming mesenchymal stem cells to “medicinal signaling cells” due to their function of repairing through cell-to-cell communication or the “paracrine effect.”

MSCs are non-blood cell-making stem cells found in every tissue of our bodies. They make up a rare proportion of the population in the bone marrow and can differentiate into bone, cartilage and fat cells. The early adult stem cell research focused on bone marrow source but one key problem arose: The quantity and potency of bone marrow stem cells decline with age as well as in the presence of chronic diseases.

Advantages of Adipose Tissue

There is more to fat than meets the eye. Whereas many researchers focus solely on the MSCs found in bone marrow, fat, umbilical cord, placenta, dental pulp and so on, in fat they are not unlike a lead singer in a band whose music is enriched and enhanced by backup singers and the other musicians. There are many other cell types in fat that work together, and we call these “regenerative cells.”

Adipose tissue functions as a protected reservoir of stem and regenerative cells throughout one’s life. The studies using bone marrow mononuclear cells (BMNCs) for bone marrow found a steep drop-off in efficacy after the age of 62.[8]

Another advantage of fat as a cell source lies in the fact that there are up to 2,500 times more MSCs in a gram of adipose tissue vs a gram of bone marrow. [9]

Fat-derived regenerative cells were first discovered in 1964 by Martin Rodbell who, using an enzyme and a centrifuge, successfully liberated a mixed population of cells from the adipose tissue of a mouse. Research on adult stem cells took a quantum leap forward in 2001, when Patricia Zuk PhD, Dr. Marc Hedrick and others working in the labs of UCLA, published a paper in Tissue Engineering discussing their discovery that mesenchymal stem cells (MSCs) reside alongside other regenerative cells in our fat.[10] With that a new era in medicine had begun.

Different Cells, Different Jobs

Adult stem cells from different cells sources work for different indications including certain blood cancers for bone marrow and umbilical cord stem cells. Bone marrow stem cells have been shown to be most effective in orthopedic and cardiac cell therapy in middle-aged or younger patients due to the declining number and potency as we age. Conversely, ADRCs are accessible, abundant and potent later in life and hence hold the most promise for age-related degenerative diseases.

[1] A Nguyen, A et al Stromal vascular fraction : Une réalité régénératrice ? Part 1 : Current concepts and review of the literature Journal of Plastic, Reconstructive & Aesthetic Surgery (2016) 69, 170e179.

[2]Guo et al Stromal vascular fraction : Une réalité régénératrice ? Part 2 : Current concepts and review of the literature Journal of Plastic, Reconstructive & Aesthetic Surgery (2016) 69, 180e188

[3]JK Fraser PhD and S Kesten MD Autologous Adipose Derived Regenerative Cells: A platform for therapeutic applications Advanced Wound Healing Surgical Technology International XXIX

[4]C Dessels et al Factors Influencing the Umbilical Cord Blood Stem Cell Industry: An Evolving Treatment Landscape Stem Cells Translational Medicine April 2018

[5]Tavassoli M, Crosby WH. Transplantation of marrow to extramedullary sites. Science. 1968;161:54–56.

[6] A. I. Caplan, Mesenchymal stem cells, Journal of Orthopaedic Research, vol. 9, no. 5, pp. 641–650, 1991

[7] A.I. Caplan MSCs – The Sentinel and Safe-Guards of Injury J. Cell. Physiol. 231: 1413–1416, 2016.  2015 Wiley Periodicals, Inc

[8] J Willerson and E Perin Buying New Soul Journal of American College of Cardiology. 2012;60(21):2250-2251.

[9] PC Baer Adipose-derived mesenchymal stromal/stem cells: An update on their phenotype in vivo et in vitro. World J Stem Cells 2014

[10] PA Zuk et al Multilineage cells from human adipose tissue : implications for cell-based therapies. Tissue Eng 2001

Thérapie cellulaire AMBROSE

Votre droit d'essayer